Actinium Pharmaceuticals, Inc (ATNM)

From the record

Actinium Pharmaceuticals, Inc's filings since 2017 show 6 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2026-08-14); an auditor change (8-K item 4.01, 2 times, the latest 2025-05-09); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2017-05-10) (its current reports).

From the record

Actinium Pharmaceuticals, Inc's 4 filed years say what it did: revenue went from $1 million in fiscal 2021 to $90 thousand in fiscal 2025, down 47% a year; it rose in 1 of 3 years; the deepest fall was 93% from fiscal 2021 to fiscal 2023; net income was positive in 0 of 5 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Actinium Pharmaceuticals, Inc lost about 433 cents for every dollar of shareholders' money. Leverage: it owed about 85 cents per dollar of assets, and net share issuance: its share count grew 3.7% over the year (the filed statements).

From the record

Actinium Pharmaceuticals, Inc's standing among 315 graded names in its industry family: revenue of $90 thousand in fiscal 2025 ranks in the bottom 8% by size; a net margin of -37652.2% ranks in the bottom 5%; revenue growth of -47% a year over the last 3 filed years ranks in the bottom 10% (its annual reports).

From the record

Actinium Pharmaceuticals, Inc's leadership, from its insiders' filings and its current reports: the chief executive on the record is Seth, Sandesh (Chief Executive Officer, as filed), filing under that title since 2017-06-15, 9.4 years (top 18% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 8.5 years (top 16%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 28%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Actinium Pharmaceuticals, Inc's room to grow, from the newest filed statements (fiscal 2025): cash of $48 million against no long-term debt tagged leaves 92.7% of its assets as net cash, top 7% of its family; cash from operations less capital spending is -27426.7% of revenue (bottom 5%); research spending of 23471.1% of revenue (top 3%) (its annual report).

From the record

Actinium Pharmaceuticals, Inc's growth drivers, from the filed years to fiscal 2025: revenue grew -47% a year over the last three filed years against -47% over all 4, speeding up (top 40% of its family); the newest year grew 5.4% (bottom 46%); research spending grew -3% a year (bottom 42%); capital spending grew -34.3% a year (bottom 34%) (its annual reports). Actinium Pharmaceuticals, Inc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Actinium Pharmaceuticals, Inc's newest year against its own record: revenue of $90 thousand in fiscal 2025 came in 317.9% above the $22 thousand its prior three years' pace pointed to (top 10% of its family); net income of $34 million against a prior three-year average of $36 million (bottom 43%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 5%) (its annual reports).